sivelestat Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Sivelestat is an inhibitor of human neutrophil elastase.   Wikipedia

Chemistry

  • SMILES: O.O.O.O.[Na+].CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)[O-]
  • InChIKey: PLHREJBSQUSUCW-UHFFFAOYSA-M
  • Mol. Mass: 528.51
  • ALogP: 2.83
  • ChEMBL Molecules:
    None  
    sivelestat sodium  
    sivelestat  
More Chemistry

Pharmacology

Alternative names

glycine, n-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)- | n-(2-(4-(2,2-dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid | ono 5046 | ono-5046 | ono-5046.na | ono-ei-600 | sivelestat | sivelestat sodium | sivelstat

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Acute Lung Injury (Phase 1/Phase 2)

Community-Acquired Infections (Phase 2)

Respiratory Distress Syndrome (Phase 4)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue